Welcome!

News Feed Item

Twice as Many People Think Cancer is a Death Sentence in the UK Compared to the US

BASINGSTOKE, England, August 23, 2013 /PRNewswire/ --

New research sheds light on UK public perceptions about cancer care

The Lilly PACE initiative this week launched the results of a survey of cancer patients, their carers and the general public around current perceptions of cancer care.

The survey, conducted in six countries across the globe, showed that in the UK although the majority of people (73%)[1] are satisfied with recent progress in the fight against cancer, half of them (42%)[1] still feel a diagnosis of cancer is a death sentence. This was double the percentage reported by American survey respondents, suggesting people in the UK have lower expectations of cancer treatment.[1]

In addition, 70%[1] of people believe current challenges facing the UK economy could stifle innovative cancer research, with a strong majority (74%)[1] believing it takes too long for new cancer medicines to reach patients. This may be a legitimate concern. In 2012 an Office of Health Economics report showed that the median time it took a newly launched drug to receive publication of NICE guidance via the Single Technology Appraisal process was over two and a half years.[2]

In the UK there was also concern about resources, with almost half (48%)[1] of those questioned believing not enough is being spent on cancer research. In addition, 72% of the general population, 87% of patients and 81% of carers think that the NHS should pay for life-prolonging treatment.[1] With the Government set to change the way drugs in the UK are priced within the next six months and NICE playing a key role in assessing medicines for funding, these are important findings about the public views. Furthermore, the Cancer Drugs Fund, used to pay for life prolonging treatments in oncology, is due to end soon.

Describing the PACE Cancer Perceptions Index, Andrew Wilson (Rarer Cancers Foundation) explained: "It is shocking to see that such a large proportion of people still see cancer as a death sentence. It is essential that the recent changes to the NHS, uncertainty over the future of the Cancer Drugs Fund and changing in drugs pricing do not represent hurdles for patients or delay their access to innovative cancer medicines. Research such as this highlights why improving cancer management should continue to be an area of government focus."

The PACE Cancer Perceptions Index also showed around half (56%)[1] of the UK public understood that incremental "small-step" advances in treatment for cancer, rather than blockbuster developments, are integral to progress when it comes to treating and managing the disease. The research also reveals how those involved in the development of cancer medicines are perceived, with pharmaceutical companies recognised as equal to academic researchers in advancing cancer treatments.

Describing the PACE Cancer Perceptions Index, Dr Mick Peake, Consultant and Senior Lecturer in Respiratory Medicine, Clinical Lead, National Cancer Intelligence Network, and Chair of the UK PACE advisory board, explained: "Step by step we are continuing to gain ground in the fight against cancer and it's great that people in the UK understand this.  However, it's important not to lose momentum especially given that our cancer survival rates lag behind many other European countries. We must build on our successes in order to make progress and, despite the slowdown in the UK economy, it is essential that steps are put into place to speed up and give patients greater access to excellence in cancer care and treatment."

Notes to editors:

About PACE

PACE stands for Patient Access to Cancer care Excellence. Created by Lilly Oncology as a global collaboration spanning diverse sectors, PACE exists to encourage public policies and health care decisions that speed the development of new medicines, promote rapid learning from patient experiences and assure that cancer care and treatment responds to the needs and qualities of individual patients. The PACE programme believes that by putting patients at the centre of cancer care we will ensure access to excellence and innovation in treatment.

About the PACE Cancer Perceptions Index

The Lilly PACE study was fielded in the UK, France, Germany, Italy, Japan, and the United States. Three respondent groups were interviewed in each country: general population, cancer patients, and cancer patient caregivers.

The survey of over 4000 people around the world included over 700 UK respondents.

All respondents in all sample groups were required to be 18 years of age or older in order to participate. Patients were screened for a cancer diagnosis in the past 5 years, having undergone at least one of the following treatments: surgery, chemotherapy (or infusional injections or oral anti-cancer drugs), or radiation therapy. The same requirements pertained to the person caregivers were helping and about whom they were responding. Data were monitored during the field period to make certain that there was a mix of different types of the most prevalent cancers. The results yielded a mix of cancers naturally. The cancers that were monitored were breast, lung, colon, and prostate.

About Lilly Oncology

For more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer and because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. Lilly has a strong heritage in oncology and has a history of developing treatments for lung, ovarian, breast and pancreatic cancer and mesothelioma

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers-through medicines and information-for some of the world's most urgent medical needs.

About Lilly UK

Lilly UK is the UK Affiliate of Eli Lilly and Company. Lilly has been operating in the UK since 1934 and employs approximately 1400 people throughout the country working in sales and marketing, research and development and bio-tech manufacturing.

1. Data on file. Eli Lilly and Company and/or one of its subsidiaries.

2. Phill O'Neill, Nancy Devlin and Ruth Puig-Peiró. Time Trends in NICE HTA Decisions. Office of Health Economics. Jan 2012. http://www.ohe.org/publications/article/time-trends-in-nice-hta-decisions-107.cfm (website accessed Aug 2013)

Contact:

Jim Baxter
Tel: +44-(0)20-7400-4480
Mobile: +44-(0)7900-605-652
Email: jbaxter@hanovercomms.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
Transforming cloud-based data into a reportable format can be a very expensive, time-intensive and complex operation. As a SaaS platform with more than 30 million global users, Cornerstone OnDemand’s challenge was to create a scalable solution that would improve the time it took customers to access their user data. Our Real-Time Data Warehouse (RTDW) process vastly reduced data time-to-availability from 24 hours to just 10 minutes. In his session at 21st Cloud Expo, Mark Goldin, Chief Technolo...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
In the fast-paced advances and popularity in cloud technology, one of the most critical factors revolves around concerns for security of your critical data. How to assure both your company and your customers they can confidently trust and utilize your cloud environment is most often top on the list. There is a method to evaluating and providing security that exceeds conventional modes of protecting data both within the cloud as well externally on mobile and other devices. With the public failure...
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, will provide a fun and simple way to introduce Machine Leaning to anyone and everyone. Together we will solve a machine learning problem and find an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intellige...